AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026)

AtaiBeckley (ATAI) reported Net Income towards Common Stockholders of -$61.1 million for Q3 2025, down 132.34% on a YoY basis from $188.8 million in Q3 2024, and down 120.25% sequentially from -$27.7 million in Q2 2025.

AtaiBeckley (ATAI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

AtaiBeckley's Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 12.68% year-over-year to -$29.8 million in Q1 2026; TTM through Mar 2026 was -$56.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$659.9 million, down 344.64% from the prior year.
  • Net Income towards Common Stockholders slipped to -$61.1 million in Q3 2025, from -$27.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$26.4 million in Q1 2025 and bottomed at -$29.8 million in Q1 2026.
  • A 5-year average of -$30.3 million and a median of -$33.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders plunged 741.53% in 2022 and surged 230.56% in 2023, its largest moves.
  • Tracing ATAI's Net Income towards Common Stockholders over 5 years: stood at -$49.3 million in 2021, then advanced by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then sank by 107.97% to -$39.0 million in 2024, then slumped by 56.64% to -$61.1 million in 2025.
  • Business Quant data shows ATAI's Net Income towards Common Stockholders at -$61.1 million in Q3 2025, -$27.7 million in Q2 2025, and -$26.4 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 AtaiBeckley 1.56 Bn 1.56 Bn - -61.07 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.78 Mn
Sep 30, 2025 -61.07 Mn
Jun 30, 2025 -27.73 Mn
Mar 31, 2025 -26.43 Mn
Mar 31, 2025 -26.43 Mn
Dec 31, 2024 -38.99 Mn
Sep 30, 2024 -26.29 Mn
Jun 30, 2024 -57.31 Mn
Mar 31, 2024 -26.71 Mn
Dec 31, 2023 -18.75 Mn
Sep 30, 2023 44.24 Mn
Jun 30, 2023 -33.04 Mn
Mar 31, 2023 -33.14 Mn
Dec 31, 2022 -40.28 Mn
Sep 30, 2022 -33.89 Mn
Jun 30, 2022 -36.62 Mn
Mar 31, 2022 -36.87 Mn
Dec 31, 2021 -49.30 Mn
Sep 30, 2021 -31.16 Mn
Jun 30, 2021 -48.46 Mn